CAS: 128196-01-0; (S)-1-(3-(Dimethylamino)Propyl)-1-(4-Fluorophenyl)-1,3-Dihydroisobenzofuran-5-Carbonitrile (Escitalopram Impurity)

结构式图片

MSDS等安全信息

欧盟法规

REACH注册ECHA物质

上下游产品

西酞普兰 1-(3-Dimethylamino-Propyl)-1-(4-Fluoro-Phenyl)-1,3-Dihydro-Isobenzofuran-5-Carbonitrile 59729-33-8
1-(4-氟苯基)-1-[3-(甲基氨基)丙基]-1,3-二氢-2-苯并呋喃-5-甲腈 (+)-Desmethylcitalopram 144025-14-9
(S)-N-Didemethyl-Citalopram 166037-78-1
(S)-1-(3-(Dimethylamino)Propyl)-1-(4-Fluorophenyl)-3-Oxo-1,3-Dihydrobenzofuran-5-Isonitrile
(+)-(R)-4-(4-Dimethylamino-1-(4'-Fluorophenyl)-1-Hydroxybutyl)-3-(Hydroxymethyl)-Benzonitrile 481047-48-7
(-)4[4-(二甲胺基)-1-(4-氟苯基)-1-(羟基丁基)-3-(羟基 甲基)氰苯.氢溴酸盐 (-)-(S)-4-(4-Dimethylamino-1-(4'-Fluorophenyl)-1-Hydroxybutyl)-3-(Hydroxymethyl)-Benzonitrile 488787-59-3
4-(4-二甲胺基-1-对氟苯基-1-羟基丁基)-3-(羟甲基)苯腈 4-[4-(Dimethylamino)-1-(4-Fluorophenyl)-1-Hydroxybutyl]-3-(Hydroxymethyl)Benzonitrile 103146-25-4
(S)-(+)-3-(5-溴-1-(4-氟苯基)-1,3-二氢异苯并呋喃-1-基)-N,N-二甲基丙烷-1-胺 (S)-(+)-3-(5-Bromo-1-(4-Fluorophenyl)-1,3-Dihydroisobenzofuran-1-yl)-N,N-Dimethylpropan-1-Amine 488148-14-7 Succinic Acid Mono-{5-Cyano-2-[(S)-4-Dimethylamino-1-(4-Fluorophenyl)-1-Hydroxybutyl]-Benzyl} Ester 863116-45-4 Tert-Butyl ((4S)-4-(4-Cyano-2-(((Tetrahydro-2H-Pyran-2-yl)Oxy)Methyl)Phenyl)-4-(4-Fluorophenyl)-4-Hydroxybutyl)(Methyl)Carbamate 1352344-90-1

合成工艺路线路线简述

    草酸右旋西酞普兰置于ammonium Hydroxide体系中,用 乙醚,水 用作溶剂,以30.1 G的收率获得依他普仑
    参考文献: New Salt And Solid State Forms Of Escitalopram[fr] Nouveau Sel Et Formes à L'état Solide D'Escitalopram
    标题: New Salt And Solid State Forms Of Escitalopram[fr] Nouveau Sel Et Formes à L'état Solide D'Escitalopram
    摘要:本公开涉及氟西汀的新盐及其固态形式,其制备方法,药物组合物以及使用方法.

    海关参考信息

    专利信息


    专利号:US-10005720-B2
    优先权日:2013-04-05
    标题:Compounds useful for the treatment of metabolic disorders and synthesis of the same
    发明人:SEXTON JONATHAN Z; BRENMAN JAY E; MUSSO DAVID L
    权利人:NORTH CAROLINA CENTRAL UNIV; UNIV NORTH CAROLINA CHAPEL HILL
    摘要:The present invention provides compounds of Formula (I): wherein variables X, Y, Z and R1 are as described herein. Some of the compounds described herein are glutamate dehydrogenase activators. The invention is also directed to pharmaceutical compositions comprising these compounds, uses of these compounds and compositions in the treatment of metabolic disorders as well as synthesis of the compounds.

    专利号:US-2006030625-A1
    优先权日:2004-08-06
    标 题 :Dietary neurotransmitter precursors for balanced synthesis of neurotransmitters
    发明人:HART CHERYLE RAM; GROSSMAN RONALD S; RAM HERBERT
    权利人:HART CHERYLE RAM; GROSSMAN RONALD S; RAM HERBERT
    摘要:Dietary supplements for treating a neurotransmitter deficiency include one or more precursors of the deficient neurotransmitter and a cofactor for activating in vivo enzymatic synthesis of the deficient neurotransmitter. The dietary supplements can also include an appropriate neurotransmitter, such as an amino acid. When administered through the oral mucosa, increases in levels of the deficient neurotransmitters and relief from deficiency symptoms are obtained.

    专利号:US-9981949-B2
    优先权日:2008-12-01
    标题 :Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine
    发明人:AKIREDDY SRINIVASA RAO; BHATTI BALWINDER SINGH; CUTHBERTSON TIMOTHY J; DULL GARY MAURICE; MILLER CRAIG HARRISON; MITCHENER JR JOSEPH PIKE; MUNOZ JULIO A; OTTEN PIETER ALBERT
    权利人:OYSTER POINT PHARMA INC
    摘要:The present invention relates to the stereospecific synthesis of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine, its salt forms, and novel polymorphic forms of these salts.

    专利号:US-8604191-B2
    优先权日:2008-12-01
    标 题:Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3YLVINYL)pyrimidine
    发明人:AKIREDDY SRINIVASA RAO; BHATTI BALWINDER SINGH; CUTHBERTSON TIMOTHY J; DULL GARY MAURICE; MILLER CRAIG HARRISON; MITCHENER JR JOSEPH PIKE; MUNOZ JULIO A; OTTEN PIETER ALBERT
    权利人:AKIREDDY SRINIVASA RAO; BHATTI BALWINDER SINGH; CUTHBERTSON TIMOTHY J; DULL GARY MAURICE; MILLER CRAIG HARRISON; MITCHENER JR JOSEPH PIKE; MUNOZ JULIO A; OTTEN PIETER ALBERT; TARGACEPT INC
    摘要:The present invention relates to the stereospecific synthesis of (R)-5-((E)-2-pyrrolidin-3-yl)pyrimidine, novel salt forms, and novel polymorphic forms of these salts.

    专利号:US-2008199922-A1
    优先权日:2005-06-22
    标题 :Chemoenzymatic Process for the Synthesis of Escitalopram
    发明人:COTTICELLI GIOVANNI; SALVETTI RAUL; BERTONI CHIARA
    权利人:ADORKEM TECHNOLOGY SPA
    摘要:A process is described for the preparation of escitalopram and the pharmaceutically acceptable salts thereof starting from 5-cyanophthalide by a process which provides an enantioselective enzymatic deacylation reaction of a complex of the formula (IV) where R represents a C 1 -C 4 alkyl residue or an aryl residue under the action of an esterase from Aspergillus niger.

    专利号:US-7598399-B2
    优先权日:2005-11-30
    标 题 :Methods for synthesis of 3-amino-1-arylpropyl indoles
    发明人:CONNOLLY TERRENCE JOSEPH; FARRELL ROBERT P; HUMPHREYS ERIC ROY; LYNCH STEPHEN M; SARMA KESHAB
    权利人:ROCHE PALO ALTO LLC
    摘要:A method comprising:n hydrogenating an indole propionamide compound of formula h nn nwith vitride, to form an aminopropyl indole compound of formula in n nwherein m, Ar, R 1 and R 2 are as defined herein. The compounds prepared by the method of the invention are useful as monoamine reuptake inhibitors useful for treatment of CNS indications.
    成都诺维尔生物医药有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.cd-novel.com
    电话: 028-85255396👤
    📞成都诺维尔生物医药有限公司 ⚠️参考联系方式

    销售电话:028-85255396
    邮箱:3196501982@qq.com
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Sanchez C, Reines EH, Montgomery SA. A comparative review of escitalopram, paroxetine, and sertraline: Are they all alike? Int Clin Psychopharmacol. 2014 Jul;29(4):185-96. doi: 10.1097/YIC.0000000000000023. Review.
    2: Pastoor D, Gobburu J. Clinical pharmacology review of escitalopram for the treatment of depression. Expert Opin Drug Metab Toxicol. 2014 Jan;10(1):121-8. doi: 10.1517/17425255.2014.863873. Epub 2013 Nov 30. Review. doi: 10.4088/JCP.14m09281. doi: 10.1186/s12888-014-0349-x.
    5: Talley NJ, Locke GR, Saito YA, Almazar AE, Bouras EP, Howden CW, Lacy BE, DiBaise JK, Prather CM, Abraham BP, El-Serag HB, Moayyedi P, Herrick LM, Szarka LA, Camilleri M, Hamilton FA, Schleck CD, Tilkes KE, Zinsmeister AR. Effect of Amitriptyline and Escitalopram on Functional Dyspepsia: A Multicenter, Randomized Controlled Study. Gastroenterology. 2015 Aug;149(2):340-9.e2. doi: 10.1053/j.gastro.2015.04.020. Epub 2015 Apr 25.

    合成参考文献


    参考文献:10.1186/1752-1947-4-6
    摘要:Baune BT, Eyre H. Anti-inflammatory effects of antidepressant and atypical antipsychotic medication for the treatment of major depression and comorbid arthritis: a case report. Journal of Medical Case Reports. 2010 Jan 12;4(1):6. doi: 10.1186/1752-1947-4-6.
    参考文献:10.1155/2011/903595
    摘要:Ooi C, Zawar V. Hyperaesthesia Following Genital Herpes: A Case Report. Dermatology Research and Practice. 2011;2011():1–3. doi: 10.1155/2011/903595.
    参考文献:10.1016/j.pnpbp.2011.06.013
    摘要:Wolkowitz OM, Wolf J, Shelly W, Rosser R, Burke HM, Lerner GK, Reus VI, Nelson JC, Epel ES, Mellon SH. Serum BDNF levels before treatment predict SSRI response in depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2011 Aug;35(7):1623–30. doi: 10.1016/j.pnpbp.2011.06.013.
    参考文献:10.2147/ndt.s19611
    摘要:Montgomery S, Briley M. Noradrenergic symptom cluster in depression. Neuropsychiatr Dis Treat. 2011;7(Suppl 1):1–2.
    参考文献:10.2147/ndt.s19613
    摘要:Blier P, Briley M. The noradrenergic symptom cluster: clinical expression and neuropharmacology. Neuropsychiatr Dis Treat. 2011;7(Suppl 1):15–20.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知